Technology | March 01, 2013

Civco Releases NonInvasive Stereotactic Radiosurgery Solution for Head, Brain Tumors

Civco Medical Solutions trUpoint ARCH Stereotactic Radiosurgery Solution

March 1, 2013 — CIVCO Medical Solutions announced the release of trUpoint ARCH, a new stereotactic radiosurgery (SRS) and stereotactic fractionated radiation (SRT) solution for head and brain tumors.

Stereotactic radiosurgery involves delivering very high doses of radiation quickly, using precisely shaped beams that focus on the tumor and minimize exposure of surrounding healthy tissues and organs. trUpoint ARCH is a frameless solution designed to effectively stabilize a patient’s head in a non-invasive, comfortable hold for delivering the high radiation doses.

“trUpoint ARCH is a solution that produces repeatable results for radiosurgery patients requiring absolute positioning. Our focus when developing new patient positioning and immobilization products is patient comfort and ease of set-up for the clinician; this solution delivers both,” said Nat Geissel, senior vice president and general manager of CIVCO’s radiation oncology business unit.

The trUpoint ARCH system provides clinicians a simple and manageable patient set-up assuring accuracy and repeatability during SRS and SRT treatments. Indexing is available on the device, nasion and the arch design allows flexibility in treatment planning around the device. Compatible with CIVCO’s Universal Couchtop, Posifix thermoplastic system, AccuForm cushions and Protura Robotic Patient Positioning System, trUpoint ARCH provides a comprehensive motion management solution for effective SRS/SRT treatment.

The first cancer center to benefit from this innovative solution is the University Hospital Zurich, Switzerland. They began using trUpoint ARCH with their radiosurgery program in late January 2013.

For more information: www.CIVCO.com

Related Content

Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...